… administered dose of 2.4 mg semaglutide on CV outcomes compared with placebo in people
without diabetes but who were living with overweight or obesity and who suffered from a …

… Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes
(STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.  …

… profile of semaglutide in the SUSTAIN 1–5 and 7 trials, and its cardiovascular safety profile
in … for the treatment of obesity, and of subcutaneous semaglutide once weekly vs. an SGLT-2 …

… risk factors with semaglutide reported here will be complemented by an ongoing cardiovascular
outcomes trial in participants with overweight or obesity and established cardiovascular …

… cardiovascular disease and overweight or obesity but without diabetes, long-term semaglutide
… progression to biochemical diabetes but does not slow glycemic progression over time. …

… liraglutide and semaglutide improved CV and renal outcomes with no apparent
differences across BMI groups. However, subgroup analysis of the EMPA-REG OUTCOME (empagliflozin…

… Disease and Stroke in Patients With Overweight or Obesity (SELECT) trial (NCT03574597) …
1 RA semaglutide on cardiovascular outcomes in participants with overweight or obesity. The …

… events as seen with subcutaneous semaglutide. The SELECT trial will assess whether
subcutaneous semaglutide improves CV outcomes in obese or overweight patients without T2D. …

… This GLP-1RA has been recently used to treat obesity at a higher dosage, even in the absence
of a … whether semaglutide is cardiovascular safe in patients with overweight or obesity, …

… In the CV outcomes trial (PIONEER 6), oral semaglutide did not increase the risk of MACE
… CVD/CKD or CV risk factors. While PIONEER 6 was not powered to show superiority for CV …